Layoffs
Merrimack said the company will preserve its cash runway in order to provide time for additional milestone payments from Ipsen.
Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
Merck & Co. filed with the U.S. Securities and Exchange Commission that it plans an extensive restructuring of its manufacturing and supply network. This will, it indicates, reduce its “global real estate footprint.”
The employees were terminated over allegations of industrial espionage on behalf of the Chinese government. MD Anderson ought to quell concerns of racial profiling following the firings.
Steps have been taken to safeguard the cancer center, including development of a cutting-edge approach to Enterprise Risk Management.
There is something of a recurring theme among the life science, healthcare and biopharma industries: shortage of skilled employees will lead to a decrease in innovation.
Since GSK initiated this new focus, the company has made several key moves to support the plan, including the December 2018 acquisition of Tesaro Oncology.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of its sales team, according to reports.
The Pennsylvania-based company disagrees with the FDA’s analysis of its clinical data and will seek to work with the agency for approval.
PRESS RELEASES
